These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11357554)

  • 1. Use of sirolimus in kidney transplantation.
    Podbielski J; Schoenberg L
    Prog Transplant; 2001 Mar; 11(1):29-32. PubMed ID: 11357554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on transplant pharmacology: sirolimus.
    Hoffmann RL; Roesch T
    Dimens Crit Care Nurs; 2004; 23(2):69-75. PubMed ID: 15192367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus for solid organ transplantation in children.
    Gupta P; Kaufman S; Fishbein TM
    Pediatr Transplant; 2005 Jun; 9(3):269-76. PubMed ID: 15910380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus-based immunosuppression: present state of the art.
    Kahan BD
    J Nephrol; 2004; 17 Suppl 8():S32-9. PubMed ID: 15599884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus: a new agent for prevention of renal allograft rejection.
    Vasquez EM
    Am J Health Syst Pharm; 2000 Mar; 57(5):437-48; quiz 449-51. PubMed ID: 10711524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target of rapamycin (TOR) inhibition in renal transplantation: Clinical uses in various populations. Introduction.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S1-2. PubMed ID: 11583937
    [No Abstract]   [Full Text] [Related]  

  • 10. [3/3 Inhibitors of mTOR (sirolimus and everolimus)].
    Chaumard N; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Sep; (718):63-4. PubMed ID: 17970580
    [No Abstract]   [Full Text] [Related]  

  • 11. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
    Kovarik JM
    Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
    Velosa JA; Larson TS; Gloor JM; Stegall MD
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
    Ponticelli C
    Transplant Proc; 2001; 33(1-2):1031-2. PubMed ID: 11267177
    [No Abstract]   [Full Text] [Related]  

  • 15. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
    Drugs R D; 1999 Jan; 1(1):100-7. PubMed ID: 10566001
    [No Abstract]   [Full Text] [Related]  

  • 18. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.